Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 16/20 | 0.87 |
| ▸ | NTSR2 | O95665 | 12/20 | 0.87 |
| ▸ | SORT1 | Q99523 | 9/20 | 0.80 |
| ▸ | NPY1R | P25929 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30472155 | 0.94 | NTSR1 (0.87) | NTSR1NTSR2SORT1 | |
| SCHEMBL29398203 | 0.94 | NTSR1 (0.87) | NTSR1NTSR2SORT1 | |
| SCHEMBL29416842 | 0.94 | NTSR1 (0.87) | NTSR1NTSR2SORT1 | |
| Demotensin 1 SCHEMBL30312742 | 0.88 | NTSR1 (1.00) | NTSR1NTSR2SORT1OPRD1 | |
| SCHEMBL29442471 | 0.88 | NTSR1 (0.71) | NTSR1NTSR2SORT1NPY1ROPRM1 | |
| SCHEMBL29361023 | 0.86 | NTSR1 (0.74) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL31280899 | 0.86 | NTSR1 (0.74) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL1421733 | 0.85 | NTSR1 (0.74) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL1421754 | 0.85 | NTSR1 (0.74) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL30880437 | 0.85 | NTSR1 (0.82) | NTSR1NTSR2SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154219-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2025-05-15 | — | — | US | disclosed |
| US-12110318-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2024-10-08 | — | — | US | disclosed |
| US-20220324935-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2022-10-13 | — | — | US | disclosed |
| US-11390657-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110318-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | NTSR1 18/4885NTSR2 25/4885SORT1 1025/4885 |
| US-20220324935-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | NTSR1 23/4885NTSR2 44/4885SORT1 1460/4885 |
| US-20250154219-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | NTSR1 23/4885NTSR2 44/4885SORT1 1460/4885 |
| US-11390657-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | NTSR1 18/4885NTSR2 25/4885SORT1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.